| 描述信息 |
Bispecific-antibody therapy (BAT), the next strategy of immunotherapy for tumor patients, has showed the enhanced antitumor benefits than the monotherapy such as anti-PD1 or anti-CTLA4. However, despite the fact that BAT had an impressive succeed in immunotherapy, the few effective biomarkers were developed to monitor the response. Plasma is the dominant sample used in clinical practice due to its non-invasive characteristic. In addition, mass spectrometry-based plasma proteomic provided a strategy to deal with the extremely large dynamic range of protein abundances, which was enhanced the plasma biomarker candidate exploration for the clinical trial. Here, we investigated the BAT longitudinal proteome profiling including longitudinal samples from tumor patients who received anti-PD1 and anti-CTLA4 BAT and explore the candicate biomarker for the therapy response. |
